May 08, 2023 / 08:30PM GMT
Operator
Good afternoon, and welcome to Enanta Pharmaceuticals Second Quarter Ended March 31, 2023 Financial Results Conference Call. (Operator Instructions) Please be advised that this call is being recorded.
I would now like to turn the call over to Jennifer Viera, Investor Relations. Please go ahead.
Jennifer Viera - Enanta Pharmaceuticals, Inc. - Senior Director of IR & Corporate Communications
Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter 2023 financial results was issued this afternoon and is available on our website. A news release with top line data from our SPRINT clinical trial was also issued this afternoon and can be found on our website as well. Slides from today's webcast will be available on our website after the call ends.
On the call today are Dr. Jay Luly, our President and Chief Executive Officer; Dr. Scott Rottinghaus, our Chief Medical Officer; Paul Mellett, our Chief Financial Officer; and Dr. Tara Kieffer, our Senior Vice President of New Product
Q2 2023 Enanta Pharmaceuticals Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot